Personalized Gait Phase Estimation for Post-Stroke Individuals via Supervised Domain Adaptation with Limited Gait Data
- Journal
- IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society (Q1)
- Published
- 6 October 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Sanguk Choi, Kyoungchul Kong
- PMID
- 42837236
- DOI
- 10.1109/TNSRE.2026.3740500
Why clinicians should know about it
- Picked for Rehabilitation (paper of the day, 7 October 2026): Personalized gait phase estimation for post‑stroke gait
Abstract
Accurate gait phase estimation is important for characterizing locomotor progression and enabling phase-dependent monitoring and intervention across gait analysis, rehabilitation, neuroprosthetic, and wearable assistive systems. However, this remains challenging in post-stroke individuals because pathological gait patterns vary substantially across subjects, while patient-specific gait data are often limited. To address this issue, this study proposes a personalized gait phase estimation framework based on supervised domain adaptation (SDA) with a multi-phase maximum mean discrepancy (MP-MMD) objective. This objective aligns source and target latent features separately during stance and swing using stride-specific toeoff labels. A shared feature extractor and domain-specific regressors are jointly trained using data from non-disabled individuals and limited labeled data from each post-stroke participant to construct a subject-specific model. Leave-One-Trial-Out evaluation of seven participants yielded a Root Mean Square Error (RMSE) of 4.37±1.26% and a Maximum Absolute Error (MaxAE) of 8.64±1.90%. After Holm correction, the proposed SDA method achieved significantly lower RMSE than Source Only and Fine-Tuning and lower MaxAE than all three baselines (all adjusted p = 0.047). Relative to Target Only and Fine-Tuning, RMSE showed numerical reductions of 13.32% and 57.51%, respectively, and MaxAE decreased by 26.50% and 72.17%. Compared with conventional global MMD, MP-MMD yielded numerical reductions of 2.87% in RMSE and 2.77% in MaxAE. These results constitute a proof-of-concept for data-efficient within-subject personalization of gait phase estimation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.